Abstract
Summary
Diabetes is the metabolic disorder that is associated with the glucose level in the blood. It is mainly divided into two types, insulin-dependent diabetes mellitus or juvenile onset (type 1) and non-insulin-dependent diabetes mellitus, or adult-onset diabetes (type 2).
LPI (LP Information)' newest research report, the “Stem Cell Therapy for Diabetes and Related Conditions Industry Forecast” looks at past sales and reviews total world Stem Cell Therapy for Diabetes and Related Conditions sales in 2022, providing a comprehensive analysis by region and market sector of projected Stem Cell Therapy for Diabetes and Related Conditions sales for 2023 through 2029. With Stem Cell Therapy for Diabetes and Related Conditions sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Stem Cell Therapy for Diabetes and Related Conditions industry.
This Insight Report provides a comprehensive analysis of the global Stem Cell Therapy for Diabetes and Related Conditions landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Stem Cell Therapy for Diabetes and Related Conditions portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Stem Cell Therapy for Diabetes and Related Conditions market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Stem Cell Therapy for Diabetes and Related Conditions and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Stem Cell Therapy for Diabetes and Related Conditions.
The global Stem Cell Therapy for Diabetes and Related Conditions market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
NSI-566 is the stem cell therapy candidate under development by one of the key companies Neuralstem. The molecule is being developed for the treatment of individuals with diabetic neuropathy and is currently in the pre-clinical development stage. The mechanism of action of this stem cell therapy includes cell replacement that eventually leads to neurogenesis stimulation.
This report presents a comprehensive overview, market shares, and growth opportunities of Stem Cell Therapy for Diabetes and Related Conditions market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Monotherapy
Combination Therapy
Segmentation by application
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetic Foot Ulcer
Diabetic Nephropathy
Diabetic Neuropathy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Athersys
Mesoblast
Caladrius Biosciences
Sanofi
Novo Nordisk
LPI (LP Information)' newest research report, the “Stem Cell Therapy for Diabetes and Related Conditions Industry Forecast” looks at past sales and reviews total world Stem Cell Therapy for Diabetes and Related Conditions sales in 2022, providing a comprehensive analysis by region and market sector of projected Stem Cell Therapy for Diabetes and Related Conditions sales for 2023 through 2029. With Stem Cell Therapy for Diabetes and Related Conditions sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Stem Cell Therapy for Diabetes and Related Conditions industry.
This Insight Report provides a comprehensive analysis of the global Stem Cell Therapy for Diabetes and Related Conditions landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Stem Cell Therapy for Diabetes and Related Conditions portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Stem Cell Therapy for Diabetes and Related Conditions market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Stem Cell Therapy for Diabetes and Related Conditions and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Stem Cell Therapy for Diabetes and Related Conditions.
The global Stem Cell Therapy for Diabetes and Related Conditions market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
NSI-566 is the stem cell therapy candidate under development by one of the key companies Neuralstem. The molecule is being developed for the treatment of individuals with diabetic neuropathy and is currently in the pre-clinical development stage. The mechanism of action of this stem cell therapy includes cell replacement that eventually leads to neurogenesis stimulation.
This report presents a comprehensive overview, market shares, and growth opportunities of Stem Cell Therapy for Diabetes and Related Conditions market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Monotherapy
Combination Therapy
Segmentation by application
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Diabetic Foot Ulcer
Diabetic Nephropathy
Diabetic Neuropathy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Athersys
Mesoblast
Caladrius Biosciences
Sanofi
Novo Nordisk
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Stem Cell Therapy for Diabetes and Related Conditions Market Size 2018-2029
2.1.2 Stem Cell Therapy for Diabetes and Related Conditions Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Stem Cell Therapy for Diabetes and Related Conditions Segment by Type
2.2.1 Monotherapy
2.2.2 Combination Therapy
2.3 Stem Cell Therapy for Diabetes and Related Conditions Market Size by Type
2.3.1 Stem Cell Therapy for Diabetes and Related Conditions Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Stem Cell Therapy for Diabetes and Related Conditions Market Size Market Share by Type (2018-2023)
2.4 Stem Cell Therapy for Diabetes and Related Conditions Segment by Application
2.4.1 Type 1 Diabetes Mellitus
2.4.2 Type 2 Diabetes Mellitus
2.4.3 Diabetic Foot Ulcer
2.4.4 Diabetic Nephropathy
2.4.5 Diabetic Neuropathy
2.5 Stem Cell Therapy for Diabetes and Related Conditions Market Size by Application
2.5.1 Stem Cell Therapy for Diabetes and Related Conditions Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Stem Cell Therapy for Diabetes and Related Conditions Market Size Market Share by Application (2018-2023)
3 Stem Cell Therapy for Diabetes and Related Conditions Market Size by Player
3.1 Stem Cell Therapy for Diabetes and Related Conditions Market Size Market Share by Players
3.1.1 Global Stem Cell Therapy for Diabetes and Related Conditions Revenue by Players (2018-2023)
3.1.2 Global Stem Cell Therapy for Diabetes and Related Conditions Revenue Market Share by Players (2018-2023)
3.2 Global Stem Cell Therapy for Diabetes and Related Conditions Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Stem Cell Therapy for Diabetes and Related Conditions by Regions
4.1 Stem Cell Therapy for Diabetes and Related Conditions Market Size by Regions (2018-2023)
4.2 Americas Stem Cell Therapy for Diabetes and Related Conditions Market Size Growth (2018-2023)
4.3 APAC Stem Cell Therapy for Diabetes and Related Conditions Market Size Growth (2018-2023)
4.4 Europe Stem Cell Therapy for Diabetes and Related Conditions Market Size Growth (2018-2023)
4.5 Middle East & Africa Stem Cell Therapy for Diabetes and Related Conditions Market Size Growth (2018-2023)
5 Americas
5.1 Americas Stem Cell Therapy for Diabetes and Related Conditions Market Size by Country (2018-2023)
5.2 Americas Stem Cell Therapy for Diabetes and Related Conditions Market Size by Type (2018-2023)
5.3 Americas Stem Cell Therapy for Diabetes and Related Conditions Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Stem Cell Therapy for Diabetes and Related Conditions Market Size by Region (2018-2023)
6.2 APAC Stem Cell Therapy for Diabetes and Related Conditions Market Size by Type (2018-2023)
6.3 APAC Stem Cell Therapy for Diabetes and Related Conditions Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Stem Cell Therapy for Diabetes and Related Conditions by Country (2018-2023)
7.2 Europe Stem Cell Therapy for Diabetes and Related Conditions Market Size by Type (2018-2023)
7.3 Europe Stem Cell Therapy for Diabetes and Related Conditions Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Stem Cell Therapy for Diabetes and Related Conditions by Region (2018-2023)
8.2 Middle East & Africa Stem Cell Therapy for Diabetes and Related Conditions Market Size by Type (2018-2023)
8.3 Middle East & Africa Stem Cell Therapy for Diabetes and Related Conditions Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Stem Cell Therapy for Diabetes and Related Conditions Market Forecast
10.1 Global Stem Cell Therapy for Diabetes and Related Conditions Forecast by Regions (2024-2029)
10.1.1 Global Stem Cell Therapy for Diabetes and Related Conditions Forecast by Regions (2024-2029)
10.1.2 Americas Stem Cell Therapy for Diabetes and Related Conditions Forecast
10.1.3 APAC Stem Cell Therapy for Diabetes and Related Conditions Forecast
10.1.4 Europe Stem Cell Therapy for Diabetes and Related Conditions Forecast
10.1.5 Middle East & Africa Stem Cell Therapy for Diabetes and Related Conditions Forecast
10.2 Americas Stem Cell Therapy for Diabetes and Related Conditions Forecast by Country (2024-2029)
10.2.1 United States Stem Cell Therapy for Diabetes and Related Conditions Market Forecast
10.2.2 Canada Stem Cell Therapy for Diabetes and Related Conditions Market Forecast
10.2.3 Mexico Stem Cell Therapy for Diabetes and Related Conditions Market Forecast
10.2.4 Brazil Stem Cell Therapy for Diabetes and Related Conditions Market Forecast
10.3 APAC Stem Cell Therapy for Diabetes and Related Conditions Forecast by Region (2024-2029)
10.3.1 China Stem Cell Therapy for Diabetes and Related Conditions Market Forecast
10.3.2 Japan Stem Cell Therapy for Diabetes and Related Conditions Market Forecast
10.3.3 Korea Stem Cell Therapy for Diabetes and Related Conditions Market Forecast
10.3.4 Southeast Asia Stem Cell Therapy for Diabetes and Related Conditions Market Forecast
10.3.5 India Stem Cell Therapy for Diabetes and Related Conditions Market Forecast
10.3.6 Australia Stem Cell Therapy for Diabetes and Related Conditions Market Forecast
10.4 Europe Stem Cell Therapy for Diabetes and Related Conditions Forecast by Country (2024-2029)
10.4.1 Germany Stem Cell Therapy for Diabetes and Related Conditions Market Forecast
10.4.2 France Stem Cell Therapy for Diabetes and Related Conditions Market Forecast
10.4.3 UK Stem Cell Therapy for Diabetes and Related Conditions Market Forecast
10.4.4 Italy Stem Cell Therapy for Diabetes and Related Conditions Market Forecast
10.4.5 Russia Stem Cell Therapy for Diabetes and Related Conditions Market Forecast
10.5 Middle East & Africa Stem Cell Therapy for Diabetes and Related Conditions Forecast by Region (2024-2029)
10.5.1 Egypt Stem Cell Therapy for Diabetes and Related Conditions Market Forecast
10.5.2 South Africa Stem Cell Therapy for Diabetes and Related Conditions Market Forecast
10.5.3 Israel Stem Cell Therapy for Diabetes and Related Conditions Market Forecast
10.5.4 Turkey Stem Cell Therapy for Diabetes and Related Conditions Market Forecast
10.5.5 GCC Countries Stem Cell Therapy for Diabetes and Related Conditions Market Forecast
10.6 Global Stem Cell Therapy for Diabetes and Related Conditions Forecast by Type (2024-2029)
10.7 Global Stem Cell Therapy for Diabetes and Related Conditions Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Athersys
11.1.1 Athersys Company Information
11.1.2 Athersys Stem Cell Therapy for Diabetes and Related Conditions Product Offered
11.1.3 Athersys Stem Cell Therapy for Diabetes and Related Conditions Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Athersys Main Business Overview
11.1.5 Athersys Latest Developments
11.2 Mesoblast
11.2.1 Mesoblast Company Information
11.2.2 Mesoblast Stem Cell Therapy for Diabetes and Related Conditions Product Offered
11.2.3 Mesoblast Stem Cell Therapy for Diabetes and Related Conditions Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Mesoblast Main Business Overview
11.2.5 Mesoblast Latest Developments
11.3 Caladrius Biosciences
11.3.1 Caladrius Biosciences Company Information
11.3.2 Caladrius Biosciences Stem Cell Therapy for Diabetes and Related Conditions Product Offered
11.3.3 Caladrius Biosciences Stem Cell Therapy for Diabetes and Related Conditions Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Caladrius Biosciences Main Business Overview
11.3.5 Caladrius Biosciences Latest Developments
11.4 Sanofi
11.4.1 Sanofi Company Information
11.4.2 Sanofi Stem Cell Therapy for Diabetes and Related Conditions Product Offered
11.4.3 Sanofi Stem Cell Therapy for Diabetes and Related Conditions Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Sanofi Main Business Overview
11.4.5 Sanofi Latest Developments
11.5 Novo Nordisk
11.5.1 Novo Nordisk Company Information
11.5.2 Novo Nordisk Stem Cell Therapy for Diabetes and Related Conditions Product Offered
11.5.3 Novo Nordisk Stem Cell Therapy for Diabetes and Related Conditions Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Novo Nordisk Main Business Overview
11.5.5 Novo Nordisk Latest Developments
12 Research Findings and Conclusion